We are committed to advancing the treatment of eye conditions such as keratoconus and corneal ectasia following refractive surgery, through the continued innovation of our corneal cross-linking technology and pharmaceuticals. We develop products that are not only state-of-the-art but uphold the highest levels of quality and safety. Source
No articles found.
We are a clinical-stage biopharmaceutical company committed to realizing the promi...
We are a clinical-stage biopharmaceutical compa...
The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectr...
The Ensign Group, Inc.'s independent operating ...
Headquartered in Santa Barbara, California, Sientra is a diversified global medica...
Headquartered in Santa Barbara, California, Sie...
ARCA was founded on the belief that a precision medicine approach to drug developm...
ARCA was founded on the belief that a precision...
MYOS RENS Technology, Inc. (NASDAQ: MYOS), a company based in Cedar Knolls, NJ was...
MYOS RENS Technology, Inc. (NASDAQ: MYOS), a co...
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics - a new scien...
LifeVantage Corporation (Nasdaq: LFVN) is a pio...
The recognized global leader in neuromodulation devices to treat blindness, the co...
The recognized global leader in neuromodulation...
Join the National Investor Network and get the latest information with your interests in mind.